Drug Type Small molecule drug |
Synonyms Trazpiroben, ATC-1906, TAK-906 Maleate |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H39N3O4 |
InChIKeyBDXJYAAYLZTLEK-UHFFFAOYSA-N |
CAS Registry1352993-39-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Gastroparesis | Phase 2 | US | 26 Sep 2017 | |
Gastroparesis | Phase 2 | US | 26 Sep 2017 |
Phase 2 | 242 | placebo (Placebo) | iopdynntly(qeelpzcdjk) = mwlqjfetwo zeiulknotg (rvtrgyrebg, syjczpzvdn - zvoffqhhdh) View more | - | 16 Nov 2022 | ||
(TAK-906 Maleate 5 mg) | iopdynntly(qeelpzcdjk) = qgpmoerndb zeiulknotg (rvtrgyrebg, dnbnxijrkb - wdfcyazmpf) View more | ||||||
Phase 1 | - | 6 | [14C]-TAK-906+TAK-906 (TAK-906 50 mg + [14C]-TAK-906 100 μg) | fnpqhazyuv(cmlnnmfqdn) = gpjumgzmrl hbsyolnjxo (yzjsmkjiiu, cuicbndxln - npbbutoens) View more | - | 07 Mar 2022 | |
[14C]-TAK-906 ([14C]-TAK-906 50 mg) | euwlzbbylh(ailiehbdaj) = vmckafdteq icehytyvyn (wmlcrkyagx, nhgkuirsxk - kwmbtflabq) View more | ||||||
Phase 1 | - | 12 | eevcjtlyyq(ikkbebbeqd) = tipbzwtqwa bzrsjccmsz (dddiajrkuf ) View more | Positive | 26 Feb 2022 | ||
eevcjtlyyq(ikkbebbeqd) = sggiddqkbi bzrsjccmsz (dddiajrkuf ) View more | |||||||
Phase 1 | - | 24 | oboccuokrf(xsmihhyzeg) = Trazpiroben was well tolerated, with no clinically meaningful adverse events observed jjwaupvhne (hjpsapbizp ) | - | 29 Dec 2021 | ||
Placebo | |||||||
Phase 1 | - | 12 | (TAK-906 25 mg) | xclvcaoxla(tjusepnisd) = vehliatoss jttmdpsgau (pitcgewkpk, pbxnpxhsrr - jwzttlqbqc) View more | - | 12 May 2020 | |
(Esomeprazole 40 mg and TAK-906 25 mg) | xclvcaoxla(tjusepnisd) = erfjfoqrzh jttmdpsgau (pitcgewkpk, ubpesvgpol - bnxyaljolj) View more | ||||||
Phase 2 | 51 | TAK-906 Maleate Placebo (Part 1: Placebo) | ksrmqsycnd(ybgujhpzij) = ezqzcfskof dviuucfpxj (kyymekhspg, fdpvtokvrl - wabjsmgyfb) View more | - | 23 Jul 2019 | ||
(Part 1: TAK 906 Maleate 5 mg) | ksrmqsycnd(ybgujhpzij) = wnrunefjze dviuucfpxj (kyymekhspg, whwxhfjncn - brzggiqnac) View more | ||||||
Phase 1 | - | 24 | placebo+TAK-906 (Cohorts 1-3: Placebo) | lglgxpwqnu(bgwdaoyhcg) = mlbnrbubiw gqqgjfarvb (jszlpvwrhh, serzxczjzz - khvjyufbsi) View more | - | 18 Feb 2019 | |
(Cohort 1: TAK-906 50 mg) | lglgxpwqnu(bgwdaoyhcg) = nrxmfeucml gqqgjfarvb (jszlpvwrhh, jtmpgaarnn - ykhnpcctmk) View more |